Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

Imunon, Inc. ( NASDAQ: IMNN) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Kimberly ...

Imunon, Inc. (($IMNN)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for Imunon, Inc.

Learn about the latest advancements in immunotherapy research focusing on harnessing IL-12 for the treatment of ovarian cancer to potentially improve survival rates.

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.

Track upcoming stock splits and reverse stock splits with ratios, payable dates, and ex-dates for U.S. traded equities with our stock split calendar.